PPCI in Patients With CABG
CABG persist 3, 5, 9 although others show either a modest 10 or no difference in outcomes. 8 Many of these studies in patients with prior CABG do not differentiate between outcomes if PPCI is performed on native vessel or in the saphenous vein graft 4, 5, 11 that may limit interpretation of outcomes.
Current STEMI guidelines do not specifically address the management of this complex group of patients in the PPCI setting, on account of the limited available evidence and limited outcome data in this cohort of patients, particularly from randomized controlled trials. This paucity of evidence may lead to delay or denial of PPCI therapy in patients with prior CABG presenting with STEMI. 5, 11 For example, in Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial, only 84% of patients with previous CABG presenting with STEMI underwent PPCI, although this was significantly higher at 93% in those patients with no prior CABG (P=0.0002). 5 Many of the previous studies have reported on outcomes in only a small number of patients, often with cohort sizes of around 100, [3] [4] [5] 9 or have been derived from cohorts in which contemporary pharmacotherapy was not used and PCI was undertaken using mainly bare metal stents or balloon angioplasty 3, 9 ; hence, the applicability of outcomes reported to contemporary practice is unclear. We therefore study early (30-day) and late (1-year) outcomes of PPCI in patients with previous CABG in a large contemporary unselected national cohort from the database of the British Cardiovascular Intervention Society (BCIS) to define whether there are differences in outcomes between native vessel infarct-related artery and bypass graft infarctrelated artery interventions in patients with previous CABG.
Methods

Study Design and Data Collection
This is a retrospective analysis of prospectively collected national data for all patients undergoing PPCI for STEMI in England and Wales from January 2007 to December 2012 in the BCIS database. BCIS records information on PCI practices in United Kingdom with data collection managed by the National Institute of Cardiovascular Outcomes Research (NICOR). [12] [13] [14] The BCIS database contains 113 clinical, procedural, and outcome variables with ≈80 000 new records added each year. Using data from the Office of National Statistics, mortality was tracked for all patients in England and Wales using the patient's unique National Health Service number. Patients from Scotland and Northern Ireland were excluded because of the absence of the Office of National Statistics-linked mortality data. Institutional review board approval was not sought for this study as all data were anonymized and routinely collected as part of a national audit.
Variables and Outcomes Collected
We collected data on participants' demographics, risk factors, and comorbidities. In addition, data were also collected on the clinical state at the time of the intervention, left ventricular ejection fraction, and all aspects of the interventional treatment and adjunctive pharmacology.
We evaluated all-cause mortality at 30-day and 1-year follow up. We also examined in-hospital major adverse cardiovascular events (MACE, defined as a composite of in-hospital mortality, in-hospital myocardial reinfarction, and target vessel revascularization) and inhospital major bleeding (defined as gastrointestinal bleed, intracerebral bleed, retroperitoneal hematoma, blood or platelet transfusion, or an arterial access site complication requiring surgery). In-hospital stroke included ischemic stroke, hemorrhagic stroke, or transient ischemic attack.
Statistical Methods
The study population was divided into 3 groups: (1) no previous CABG, (2) prior CABG with PPCI to native coronary arteries, and (3) prior CABG with PPCI to bypass grafts. Patients with missing values for follow up time, sex, and age were also excluded. The characteristics of patients were compared across the 3 groups of interest (pairwise) and also across inclusion and exclusion because of missing data. These comparisons were performed using Fisher's exact tests for binary/categorical and aaalysis of variance for continuous variables.
To be more inclusive with the data to analyze, account for missing data, and better protect against biases because of informative missing data mechanisms, we used multiple imputation with chained equations to impute data for all variables with missing information. Age, sex, group of participant, and study outcomes were registered as complete variables in the imputation models which were used to generate 10 data sets on which we ran the analyses (incomplete and imputed variables were smoking status, diabetes mellitus, hypertension, hyperlipidemia, previous myocardial infarction, previous stroke, peripheral vascular disease, renal disease, family history, radial access site, glycoprotein IIb/IIIa, shock, circulatory support, number of stents, thrombus aspiration, mechanical ventilation, femoral closure device, and left ventricular ejection fraction). The STATA code and output of the imputations is shown in the Data Supplement.
The risk of adverse outcomes by comparison group was estimated with univariable and multivariable logistic regressions. The
WHAT IS KNOWN
• There are limited data about outcomes of STsegment-elevation myocardial infarction patients with previous coronary artery bypass grafting (CABG) who undergo primary percutaneous coronary intervention.
• Many of the existing studies are limited because of small sample size.
WHAT THE STUDY ADDS
• This large study found that patients with previous CABG are older and have more comorbid conditions and adverse procedural variables than non-CABG patients having percutaneous coronary intervention.
• After adjustment for baseline differences, patients with previous CABG are not at increased risk of 30day or longer-term mortality compared with patients not having CABG. Group 1: Primary PCI in native coronary arteries; Group 2: Primary PCI in native coronary arteries in patient with CABG; Group 3: Primary PCI in bypass grafts. CVA indicates cerebrovascular accident; DES, drug-eluting stent; LAD, left anterior descending; LVEF, left ventricular ejection fraction; MI, myocardial infarction; and PCI, percutaneous coronary intervention. PPCI in Patients With CABG former were not controlled for any covariates, whereas the latter were controlled (adjusted) for various patient characteristics. Covariates in the models included age, sex, smoking status, diabetes mellitus, hypertension, hyperlipidemia, previous myocardial infarction, previous stroke, peripheral vascular disease, renal disease, family history, radial access site, glycoprotein IIb/IIIa, multivessel PCI, shock, circulatory support, number of stents, thrombus aspiration, mechanical ventilation, femoral closure device, left ventricular ejection fraction, PCI to left main stem, PCI to left anterior descending artery, and distal protection device.
We used multiple imputations with propensity score matching (mi estimate:teffects psmatch) to estimate the average treatment effect to account for baseline difference across the groups of participants. We used 2 separate multiple imputation logistic regression models for which we calculated propensity scores for each group member: (1) PCI to native vessel no graft (group 0) versus PCI to native vessel in patient with graft (group 1); and (2) PCI to native vessel no graft (group 0) versus PCI to graft (group 2). The scores were then used to perform the matching, and simple logistic regression was run (the only predictor being group membership) to obtain the average treatment effect.
We performed additional Kaplan-Meier survival analysis and Cox proportional hazards regression analysis for 30-day mortality and 1-year mortality by participant group. Statistical analyses were performed using Stata version 13.1 (Stata Corp, TX).
Results
Study Cohort
The study cohort consisted of 79 295 participants who had PPCI for STEMI in England and Wales and did not have missing values for death, follow-up, sex, and age. The process of participant inclusion is shown in Figure 1 . A total of 76 637 (96.6%) patients had no previous CABG, whereas 2658 (3.4%) patients had prior CABG. Among patients with prior CABG, 44% (n=1168) patients received PPCI to native vessels and 56% (n=1490) underwent PPCI to bypass grafts. The mean follow-up for these participants was 2.4±1.6 years, and 86.5% of patients were followed-up for a minimum of 1 year (or until death if occurring within a year).
Characteristics of Participants
There were significant differences in the demographic, clinical, and procedural characteristics of the 3 groups (Table 1) . Patients with previous CABG were significantly older and had a higher prevalence of diabetes mellitus, hypertension, peripheral vascular disease, and previous myocardial infarction or a stroke. The characteristics of those included in the study and those excluded are shown in Table I in the Data Supplement.
Unadjusted Outcomes
There was a significant difference in unadjusted mortality and in-hospital MACE among the 3 groups ( Table 2) . Figure 2A and 2B shows the unadjusted Kaplan-Meier survival curves for the 3 groups at 30 days ( Figure 2A ) and 1 year ( Figure 2B ) with significant differences in survival between the 3 groups noted (log-rank test; P<0.001 and P<0.0001 for 30-day and 1-year mortality, respectively).
Patients with prior CABG (with primary PCI to native artery or graft) had higher mortality at 30 days (6.2% with PPCI to native artery, 6.1% with PPCI to bypass graft) than patients with no prior CABG (4.5%; P<0.001). Similar observations were recorded for 1-year mortality, with the lowest rates observed in patients with no previous history of CABG (9.1%) with similar rates in patients with previous CABG and PCI to native vessels and bypass grafts (14.5% versus 11.9%; P<0.001).
In-hospital MACE rates, were higher in patients with prior CABG undergoing native vessel PCI (6.0%) compared with prior CABG undergoing PCI to a bypass graft (4.7%) or no prior CABG (4.2%). In contrast, in-hospital stroke rates and in-hospital bleeding rates were similar across all 3 groups: 0.3% versus 0.2% versus 0.2%, respectively, for stroke and 0.8% versus 0.9% versus 0.7%, respectively, for in-hospital bleeding. Similarly, for in-hospital MACE, there were no significant differences in outcomes between PPCI undertaken in native coronary arteries in patients with previous CABG and PPCI in bypass grafts compared with PPCI in native coronary arteries once differences in baseline covariates were adjusted for PPCI to native arteries in patients with CABG (OR 0.95, 95% CI 0.71-1.26; P=0.72) and PPCI to bypass grafts (OR 0.93, 95% CI There were no significant differences after adjustments with and without imputations and for all evaluations for risk of in-hospital stroke (OR 0.56, 95% CI 0.14-2.30; P=0.42 and OR 0.69, 95% CI 0.22-2.21; P=0.53, respectively) and in-hospital bleeding (OR 0.95, 95% CI 0.50-1.81; P=0.88 and OR 0.74, 95% CI 0.39-1.43; P=0.38, respectively).
Cox proportional hazards regression yielded similar results to those of unadjusted and adjusted logistic regressions for 30-day and 1-year mortality ( Table II in 
Outcomes With Propensity Score-Matching
We performed a propensity-matching to correct for baseline characteristics (balance diagnostics for propensity model presented in Table III in the Data Supplement), and there were no differences in outcomes between patients with or without previous CABG or in patients with previous CABG where PCI was performed in either the native vessel or the graft (Table 4 ).
Discussion
This study from a national unselected cohort represents the largest analysis of patients with prior CABG undergoing PPCI in the literature. We show that patients with prior CABG are older, have more comorbidities, and have adverse procedural characteristics, but once these differences are adjusted for, patients with prior CABG have similar clinical outcomes after PPCI to patients without prior CABG.
Our unadjusted analysis shows that patients with a history of CABG have the highest mortality and MACE after PPCI when compared with patients with no CABG irrespective of whether the PCI is undertaken in the native coronary vessel or the bypass graft. Patients with a prior CABG have higher comorbid burden and an overall higher adverse risk profile, which may contribute to poor outcomes observed. Indeed, patients with previous CABG undergoing PCI to native vessels had significantly higher rates of cardiogenic shock presentation, mechanical ventilator support, and circulatory support. Once adjustment is undertaken for such confounding risk factors, no statistically significant differences in clinical outcomes are seen between patients with or without prior CABG undergoing PPCI, irrespective of whether the PCI is performed in the native vessel or graft.
Previous studies have suggested that patients with prior CABG may have adverse outcomes when presenting with STEMI and treated with PPCI. These studies were either small-scale single-center registries or post hoc analysis of small numbers of patients derived from randomized controlled trial. In the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial, patients with previous CABG (n=128) had increased 90-day mortality that CABG indicates coronary artery bypass graft; MACE, major adverse cardiovascular events; and PCI, percutaneous coronary intervention.
*Adjusted for age, sex, smoking status, diabetes mellitus, hypertension, hyperlipidemia, previous myocardial infarction, previous stroke, peripheral vascular disease, renal disease, family history, radial access site, glycoprotein IIb/IIIa inhibitor, multivessel, PCI to left anterior descending artery, PCI to left main artery, shock, circulatory support, no of stents, thrombus aspiration, ventilation, femoral closure device, distal protection device, and symptom to balloon with 10 imputations for all variables. PPCI in Patients With CABG remained significant after multivariable adjustment (hazard ratio 1.9, 95% CI 1.08-3.33; P=0.025). 3 In HORIZONS-AMI trial, previous CABG (n=105) was associated with a higher incidence of MACE (36.4% versus 21.4%; P<0.001) and mortality (11.2% versus 6.7%; P=0.08) at 3 years. 5 In Second Primary Angioplasty in Myocardial Infarction (PAMI-2) trial, patients with previous CABG (n=58) were reported to have higher in-hospital (9.4% versus 2.6%; P=0.02) and 6-month (14.3% versus 4.1%; P=0.001) mortality. 9 A small registry from New York hospitals reported that patients with previous CABG presenting with STEMI (n=93) had higher unadjusted in-hospital mortality and MACE, and on multivariate analysis, prior CABG (hazard ratio 3.40; 95% CI 1.15-10.00) was independently associated with in-hospital mortality. 4 In another study of 192 patients undergoing PPCI with a saphenous vein graft, culprit were shown to have higher unadjusted rates of mortality at 30 days and MACE at 1 year, although these effects were only modest after multivariable adjustment. 10 A more recent analysis, from Kohl et al, of 249 patients with prior CABG undergoing PPCI has suggested no significant differences in unadjusted rates of in-hospital death (4.8% versus 5.9%; P=0.49), MACE at 30 days (6.8% versus 7.4%; P=0.76; including stroke, recurrent infarction, recurrent ischemia, or death), or rates of hospital readmission at 30 days (1.7% versus 2.3%; P=0.82) between PPCI in patients with previous CABG compared with those with no history of CABG, although no adjustments were made for differences in baseline covariates. 8 Furthermore, no significant differences in mortality or MACE outcomes were observed in those patients with previous CABG who underwent PCI to either the graft or the native vessel. 8 An overview of these studies is presented in Table IV in the Data Supplement.
Our data suggests differences in the unadjusted clinical outcomes in patients with previous history of CABG, although once differences in baseline comorbid conditions and procedural characteristics were adjusted for, outcomes were similar to those observed in patients without prior CABG. It has been well documented that patients with prior CABG presenting with STEMI are less likely to be offered PPCI than patients without prior CABG with similar observations recorded in patients with non-ST-segment-elevation myocardial infarction. 15 In APEX-AMI, PCI was performed less frequently in patients with prior CABG compared with those with no history of CABG (78.9% versus 93.9%; P<0.001), 3 with similar findings reported by the HORIZON-AMI investigators and the PAMI-2 study. 9 Similarly, in older studies, such as reports derived from the National Registry of Myocardial Infarction (NRMI)-3, patients presenting with STEMI with prior CABG were significantly less likely to receive PCI or thrombolysis than those without prior CABG. 16 This practice may be influenced by the paucity of data in patients with prior CABG undergoing PPCI and the perceived lack of efficacy of PPCI in these patients.
Previous reports have debated whether the outcomes are different if PPCI is performed on native vessel or saphenous vein graft in patients with previous CABG. 3, 5, [17] [18] [19] Although PPCI to vein grafts is often more technically challenging and complex, our data show no significant difference in adjusted outcomes in patients with prior CABG undergoing native or bypass graft PPCI. Our analysis has several strengths. The BCIS data set includes an almost complete collection of all PCI procedures performed in the United Kingdom representing unselected real-world experience, including high-risk patient often excluded from randomized controlled trials, and represents the largest analysis of primary PCI for STEMI patients with previous CABG to be reported.
We recognize that this study has several potential limitations. First, although mortality tracking within the United Kingdom is robust, all other outcomes and complications are self-reported without formal adjudication. Therefore, the analysis is potentially vulnerable to reporting biases, and complications may be under-reported. Second, although this analysis reports on outcomes in patients undergoing PPCI, previous studies have suggested that PPCI is less likely to be performed when the infarct-related vessel was a bypass graft rather than a native coronary artery, 9 which may contribute to selection/ referral biases in our cohort. The BCIS data set does not record information regarding patients who presented with STEMI but were medically managed and so cannot exclude significant referral or selection bias particularly for those patients with previous CABG similar to other studies. 3, 5, 16 Third, our analysis report outcomes derived from grafts because the BCIS data set does not differentiate between venous and arterial grafts. Previous data derived from the National Cardiovascular Data Registry (NCDR) CathPCI registry suggests that arterial grafts represented 2.5% of all PCI procedures undertaken to bypass grafts in the United States, although this did not report practice or outcomes in a primary PCI cohort specifically. 17 In conclusion, our data demonstrate that after adjusting for comorbidities, PPCI for STEMI results in similar outcomes for patients who have had previous CABG (either in a native vessel or a bypass graft) when compared with those who have not had previous CABG. PPCI for STEMI should be the primary treatment strategy for patients who have had previous CABG.
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